Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Free Report

White Paper_2017_State of China Life Science

State of China Life Science - 2017H1

Over $10B invested in last 18 months! 

China Clinical Trials 2017

Analysis of IND and NDA applications and approvals in China 2011-2017

Download free report on life science investment in China

Recent Articles

Week in Review: Fosun in $2 Billion Bidding War for US Rights to Novartis' Generic Drugs
CR Pharma in Talks for $613 Million Acquisition of Jiangzhong Pharma
BeiGene Starts China Trial of PARP Inhibitor in Ovarian Cancer Patients
WuXi Biologics Plans Another New CDMO Plant -- A $240 Million Facility in Shijiazhuang
Innovent Reports Positive Results for PD-1 Candidate; Files China NDA
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Events
The 9th China Healthcare Investment Conference
Shanghai, China
March 27-29, 2018
Use chinabio18 for 20% discount